Our policy on transparency is clear - we will be transparent and accountable for how we operate and the transactions that take place when and where we work.

This is a part of Novo Nordisk’s company values expressed in the  Novo Nordisk Way  and  in our Business Ethics Compliance Framework, and how we earn and retain trust and confidence.

Novo Nordisk is disclosing direct and indirect payments (transfers of value) in line with the EFPIA Code of Practice. Each affiliate has disclosed according to local EFPIA association requirements. The EFPIA Self Certification Letter for 2021 is signed by Lars Fruergaard Jørgensen, Presiden and Chief Executive Officer, Novo Nordisk. 

Novo Nordisk's Self Certification Letter (PDF)

Click here to see our locations and access our European affiliate disclosures according to local EFPIA association requirements.


Quick links to Novo Nordisk affiliates' websites in European region:

Austria, BelarusBulgaria, Bosnia, BulgariaCroatiaCyprus
Czech RepublicEstoniaFinland
GermanyGreeceHungaryIreland
ItalyLatviaLithuania, MacedoniaMalta
NorwayPolandRussiaSerbia
SlovakiaSloveniaSpainSweden
SwitzerlandUkraineUnited Kingdom

The Modern Slavery Acts require companies in scope to produce a statement which must set out what steps they have taken during the financial year to ensure that modern slavery is not occurring in their supply chains or in their own organisations.

The Acts require companies to be transparent about their actions in addressing and preventing modern slavery and expects continuous improvement year on year. The Acts require that companies annually publish a statement on their external website with a link to a prominent place on their homepage. 

Read our statement on Modern Slavery Acts:

2017   2018   2019 2020 2021 2022 2023

Statement on Due Diligence Processes Covering Child Labour Risks
Read our latest statement on due diligence processes covering child labour risks.

2023

We must collaborate with many parties on our mission to improve treatments for serious chronic diseases, such as diabetes, obesity, haemophilia and growth disorders.  This includes providing as much information as we can to healthcare professionals, institutions, and patients about proper use of the medicines and the drug delivery systems we manufacture.

Collaborations with physicians, research organisations, healthcare institutions and patient organisations help us understand and identify unmet medical needs, drive innovation and develop new medicines and enhance the quality of health education.

We meet all compliance requirements for disclosure of our financial relationships related to our collaborations with the medical community, as spelled out by relevant decrees and industry guidelines, as well as local laws, including:

  • Danish Medicines Act 
    ‘Lægemiddelloven’
  • European Federation of Pharmaceutical Industries and Associations [EFPIA] 
  • ‘Transfers of value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations’
  • French National Councils 
  • ‘Bertrand Act’ or ‘French Sunshine Act’
  • Japan Pharmaceutical Manufacturers Association 
  • ‘Transparency Guideline for the Relation between Corporate Activities and Medical Institutions’
  • United Kingdom, Prescription Medicines Code of Practice Authority 
  • ‘The ABPI Code of Practice for the Pharmaceutical Industry’
  • United States Patient Protection and Affordable Care Act Section 6002 
  • ‘Open Payments’ or ‘Sunshine Act’

We believe that transparent disclosure of financial relationships with healthcare professionals and institutions with whom we collaborate is very important to maintaining trust-based relationships and earning the public's trust.

Our position on conflict minerals
We are committed to conducting our business in a financially, environmentally and socially responsible way. This is our Triple Bottom Line principle, which we apply in order to be a sustainable business. We conduct our business with respect for human rights and in compliance with all applicable laws and fair labour practices.

The U.S. Securities and Exchange Commission requires companies whose shares are traded on U.S. stock exchanges to annually disclose whether the products they manufacture or contract to manufacture contain conflict minerals that are necessary to the functionality or production of such products that were sourced from the DRC or adjoining countries.

Read our Conflict Minerals Disclosure 2024

Partnerships and collaboration with patient organisations are essential to our mission of driving change to defeat serious chronic diseases. These interactions provide us with valuable insights into how the lives of people with chronic diseases are affected and the barriers they encounter to living their life to the full.  

In addition, assistance from pharmaceutical companies like ours helps patient organisations do  their work in support of patients and their caregivers.

We collaborate with patient organisations in an open and transparent manner to ensure respect of their independence and integrity and adherence with our own ethical standards. Our support is based on written agreements that clearly state the purpose of the support as well as the amount and a description of indirect support and any significant non-financial support.

National collaboration with patient groups
Lists of national collaborations with patient organisations can be found at the Novo Nordisk affiliates’ websites.

Quick links to Novo Nordisk affiliates' websites in European region:

AustriaBelgium (fr), (nl)BulgariaCroatia
Czech RepublicDenmarkEstoniaFinland
FranceGermanyGreeceHungaryIreland
ItalyLatvia, Lithuania, Netherlands, Norway
Poland, Portugal, Serbia, Slovakia, Slovenia
Spain, Sweden, Switzerland, Turkey, United Kingdom


Disclosure from Novo Nordisk affiliates in the European region with no website 

FYROM - Macedonia

International collaboration with patient groups
For list of collaborations with international patient organisations, select one of the links below: